Another Monster Biotech Deal: BMS Acquires Celgene for $74B
What a deal (https://news.bms.com/press-release/corporatefinan…).
Interesting that CVP aren't financial advisors for either side...
Thoughts?
What a deal (https://news.bms.com/press-release/corporatefinan…).
Interesting that CVP aren't financial advisors for either side...
Thoughts?
| +305 | I Snuck Into UBS Office And Took A Shit On The Floor | 28 | 1d |
| +291 | TPH V.S. Mizuho [HOU] | 36 | 2d |
| +248 | Houston 2026 Oil & Gas Investment Banking Rankings | 61 | 2h |
| +244 | Why leave restructuring for M&A? | 30 | 1d |
| +232 | Best Power/Renewables/Energy Teams? | 39 | 7h |
| +193 | Predicted 1Q 2027 Story - UBS IB blames Outlook Outage for Down Quarter | 36 | 11h |
| +187 | Centerview HC group falling off? | 30 | 1d |
| +184 | Actual EB List | 27 | 1d |
| +180 | Incoming TPH Analysts Larping as PWP on LinkedIn | 26 | 4h |
| +21 | What’s the current state of IBD at BofA? | 26 | 14h |
Career Resources
Et odio est rerum id. Vel blanditiis amet dolorem. Qui voluptate accusamus sit quod doloremque. Rerum mollitia alias amet. Reprehenderit omnis quas voluptatem accusamus voluptas ducimus assumenda.
Voluptas voluptatem recusandae aut nulla mollitia repellat. Autem magnam et autem minima ut perspiciatis consectetur.
Voluptas odio iure deserunt nisi inventore minima pariatur. Qui nesciunt eveniet ipsa quo et.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...